What the FDA labels say about taking them together
Certolizumab and natalizumab
Certolizumab's FDA label of February 24, 2026 names natalizumab in its drug interactions section; the natalizumab labels PlainMeds reads (2) do not name certolizumab. The certolizumab label: “Therefore, the use of CIMZIA in combination with anakinra, abatacept, rituximab, or natalizumab is not recommended.”
Check it at the source: the certolizumab FDA label on DailyMed (effective February 24, 2026, UCB, Inc.); the natalizumab FDA label on DailyMed (effective March 21, 2025, Biogen Inc.).
What does the certolizumab label say about natalizumab?
Certolizumab label, drug interactionsTherefore, the use of CIMZIA in combination with anakinra, abatacept, rituximab, or natalizumab is not recommended [see Warnings and Precautions (5.8) ].
Certolizumab label, warnings and precautionsAdvise patients to seek immediate medical attention if symptoms develop; consider discontinuing CIMZIA in patients with confirmed abnormalities. ( 5.7 ) Use with Anakinra, Abatacept, Rituximab and Natalizumab:
Source: FDA drug label (Cimzia), BLA125160 (Ucb Inc), as published by UCB, Inc., effective February 24, 2026 (SPL set b4c2c9dc-a0bb-4d64-a667-a67ebe88392d), via openFDA; the full label on DailyMed
What does the natalizumab label say about certolizumab?
Natalizumab's label (effective March 21, 2025) and its 1 other brand-application label do not name certolizumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (TYSABRI), Biogen Inc., effective March 21, 2025 (SPL set c5fdde91-1989-4dd2-9129-4f3323ea2962), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Certolizumab | Natalizumab | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | Multiple sclerosis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $6,094.02 per syringe 2x200 mg/mL syringe kit | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once